Health Catalyst (HCAT) announced a strategic partnership with Microsoft (MSFT) to help healthcare organizations accelerate operational, clinical, and financial performance through AI-driven innovation. The collaboration further builds on Health Catalyst’s expertise with Microsoft Azure and Azure AI Foundry capabilities, equipping healthcare organizations with advanced AI solutions to accelerate time to value, enhance care delivery, and drive measurable, long-term improvement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $6.50 from $7 at Citi
- Health Catalyst price target lowered to $5 from $7 at KeyBanc
- Health Catalyst downgraded to In Line from Outperform at Evercore ISI
- Health Catalyst: A Strategic Buy Amidst Promising Growth and Platform Potential
- Health Catalyst: A Buy Opportunity Amidst Market Overreaction and Promising Growth Prospects